Randomised clinical trial: Vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 10, 2015, Pages 1170-1181

  Feagan, B G ^a   Sandborn, W J ^b   D'Haens, G ^c   Lee, S D ^d   Allez, M ^e   Fedorak, R N ^f   Seidler, U ^g   Vermeire, S ^h   Lawrance, I C ^i,j   Maroney, A C ^k   Jurgensen, C H ^k   Heath, A ^k   Chang, D J ^k  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF ALBERTA   (Canada)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j ST JOHN OF GOD HOSPITAL   (Australia)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALGRANULIN; PLACEBO; VERCIRNON; CC CHEMOKINE RECEPTOR 9; CCX282-B; CHEMOKINE RECEPTOR CCR; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART DISEASE; HEPATITIS E; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FECES; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; RECEPTORS, CCR; SULFONAMIDES; YOUNG ADULT;

EID: 84943591058     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13398     Document Type: Article

References (25)

1. Baumgart DC, Sandborn WJ,. Crohn's disease. Lancet 2012; 380: 1590-605.
2. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
3. Cohen R,. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1603-9.
4. Koenecke C, Förster R,. CCR9 and inflammatory bowel disease. Exp Opin Ther Targets 2009; 13: 297-306.
5. Loftus E, Schoenfeld P, Sandborn W,. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60.
6. Podolsky DK,. Medical progress: inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
7. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, et al,. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373-80.
8. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ,. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158: 2099-106.
9. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al,. Treatment of active Crohn's disease with MLN0002: a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
10. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J, Sands BE, et al,. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
11. Hanauer SB,. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis 2009; 27: 536-41.
12. Afif W, Loftus EV Jr,. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am 2010; 94: 115-33.
13. Eksteen B, Adams DH,. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010; 13: 472-781.
14. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, et al,. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006; 131: 1518-29.
15. Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, et al,. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS ONE 2013; 8: e60094.
16. Keshav S, Ungashe S, Zheng W, Bekker P, Wright K, Schall TJ,. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, in a randomized, double-blind, placebo-controlled phase 2 study in moderate to severe Crohn's disease. Gastroenterology 2007; 132: 1031.
17. Best WR, Becktel JM, Singleton JW, Kern F,. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-44.
18. Vicari AP, Figueroa DJ, Hedrick JA, Foster JS, Singh KP, Menon S, et al,. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997; 7: 291-301.
19. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD, et al,. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000; 165: 5069-76.
20. Wurbel M, Philippe J, Nguyen C, Victorero G, Freeman T, Wooding P, et al,. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000; 30: 262-71.
21. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al,. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
22. Sands BE, Feagan BG, Rutgeerts P, Colombel J, Sandborn WJ, Sy R, et al,. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology 2014; 147: 618-27.e3.
23. Electronic Medicines Compendium (EMC) Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion-vedolizumab; 2014. Available at: http://www.medicines.org.uk/emc/PIL.28981.latest.pdf (accessed December, 4, 2014).
24. Apostolaki M, Manoloukos M, Roulis M, Wurbel M, Müller W, Papadakis KA, et al,. Role of β7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134: 2025-35.
25. Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M, et al,. Gut-associated lymphoid tissue-primed CD4 + T cells display CCR9-dependent and -independent homing to the small intestine. Blood 2006; 107: 3447-54.